TORONTO--(BUSINESS WIRE)--Biovail Corporation (NYSE:BVF)(TSX:BVF) announced today that, on May 8, 2009, the United States District Court for the Southern District of New York issued a decision dismissing with prejudice a purported securities fraud lawsuit against Biovail and several of its present and former officers and directors (Fort Worth Employees’ Retirement Fund v. Biovail Corporation, et al., No. 08 Civ. 8592). The complaint related to statements alleged to have been made by the Company and by certain officers in respect of Aplenzin™ (bupropion hydrobromide tablets) during the product’s U.S. regulatory approval process.
